Aktienanalyse zu Scribe Therapeutics Inc. Common Stock (SCTX)SCTXScribe Therapeutics Inc. Common Stock

Scribe Therapeutics, Inc. is a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention. It focuses on cardiovascular and metabolic (CVM) diseases with initial programs to address the key drivers of atherosclerotic cardiovascular disease (ASCVD). The Company's lead product candidate, STX-1150, is an epigenetic silencing therapy that is based on its ELXR technology and is designed to durably lower LDL-C for years to decades by repressing the expression of PCSK9, a genetically and clinically validated target. STX-1150 is designed to achieve long-lasting therapeutic benefit without permanently altering the underlying DNA sequence. Its pipeline also includes STX-1200 and STX-1400, target two additional lipid drivers of ASCVD, elevated Lp(a) and severely high triglycerides, by editing the LPA and APOC3 genes, respectively. It operates in the Healthcare sector.

Scribe Therapeutics is currently trading at $15.54, which is significantly below the analyst price target of $60, indicating potential for substantial upside. However, the RSI is at 32.944, suggesting the stock is oversold, which could lead to a short-term rebound. The company has reported a gross margin of 100%, but it is facing significant net losses, with a net income of -6.48 million in Q2 2026. The main risk is the company's negative earnings per share of -0.37 and ongoing concerns about long-term profitability and market acceptance of its gene-editing platform.